MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 - Germany

This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

: mii-exa-onko-cdk46-class-medication

Raw xml | Download


<MedicationRequest xmlns="http://hl7.org/fhir">
  <id value="mii-exa-onko-cdk46-class-medication"/>
  <meta>
    <profile
             value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/StructureDefinition/mii-pr-onko-therapieempfehlung-medikation|2027.0.0-ballot.1"/>
  </meta>
  <language value="de"/>
  <text>
    <status value="generated"/>
    <div xml:lang="de" lang="de"><hr/><p><b>German</b></p><hr/><p class="res-header-id"><b>Generated Narrative: MedicationRequest mii-exa-onko-cdk46-class-medication</b></p><a name="de-mii-exa-onko-cdk46-class-medication"> </a><a name="de-hcmii-exa-onko-cdk46-class-medication"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-mii-pr-onko-therapieempfehlung-medikation.html">MII PR Onkologie Therapieempfehlung Medikation</a> version: 2027.0.0-ballot.1</p></div><p><b>status</b>: Active</p><p><b>intent</b>: Option</p><p><b>medication</b>: <span title="Codes:{http://fhir.de/CodeSystem/bfarm/atc L01EF}">CDK4/6 Inhibitor (Klasse L01EF) - Palbociclib, Ribociclib oder Abemaciclib</span></p><p><b>subject</b>: <a href="Patient-mii-exa-onko-molecular-board-patient.html">Maria Müller  Female, DoB: 1968-07-22 ( https://www.medizininformatik-initiative.de/fhir/sid/patienten#MTB-2024-001)</a></p><p><b>authoredOn</b>: 2024-01-15</p><p><b>reasonReference</b>: <a href="Condition-primaertumor-example.html">Condition Bösartige Neubildung: Brustdrüse, nicht näher bezeichnet</a></p><p><b>note</b>: </p><blockquote><div><p>Molekulares Tumorboard empfiehlt beliebigen CDK4/6 Inhibitor basierend auf HR+/HER2- Profil. Konkrete Wirkstoffauswahl nach Verfügbarkeit und Patientenfaktoren.</p>
</div></blockquote></div>
  </text>
  <status value="active"/>
  <intent value="option"/>
  <medicationCodeableConcept>
    <coding>
      <system value="http://fhir.de/CodeSystem/bfarm/atc"/>
      <code value="L01EF"/>
      <display value="Cyclin-abhängige Kinasen (CDK)-Inhibitoren"/>
    </coding>
    <text
          value="CDK4/6 Inhibitor (Klasse L01EF) - Palbociclib, Ribociclib oder Abemaciclib"/>
  </medicationCodeableConcept>
  <subject>🔗 
    <reference value="Patient/mii-exa-onko-molecular-board-patient"/>
  </subject>
  <authoredOn value="2024-01-15"/>
  <reasonReference>🔗 
    <reference value="Condition/primaertumor-example"/>
  </reasonReference>
  <note>
    <text
          value="Molekulares Tumorboard empfiehlt beliebigen CDK4/6 Inhibitor basierend auf HR+/HER2- Profil. Konkrete Wirkstoffauswahl nach Verfügbarkeit und Patientenfaktoren."/>
  </note>
</MedicationRequest>